FeganScott filed a national class action lawsuit against Allergan, the manufacturers of BIOCELL textured and “gummy” breast implants. The suit claims that, although the FDA issued a recall for Allergan’s BIOCELL products, the company has no plans to provide true costs of implant removal or medical monitoring for individuals at risk of developing breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
According to the suit, Allergan refuses to appropriately care for, monitor and compensate individuals who seek to remove the recalled implants or undergo invasive and expensive diagnostic procedures. The suit also claims that beginning in at least 2006, Allergan possessed information and evidence demonstrating that its recalled BIOCELL implants posed a significant risk of BIA-ALCL.
The suit seeks to represent all U.S. consumers who, for personal use, implanted Allergan’s BIOCELL products that have been recalled by the FDA and who have not been diagnosed with breast implant-associated anaplastic large cell lymphoma.